Does Network Health Cover Wegovy?
The verdict
Conditional on most plans
Network Health's Wegovy coverage for weight loss is employer-dependent on commercial plans and not publicly published. The plan serves Wisconsin with both commercial and Medicare Advantage books, so coverage varies significantly by line of business: commercial members need employer opt-in, while Medicare Advantage members face the statutory Part D weight-loss exclusion (CV indication only). Verify on Network Health's drug-lookup tool.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Network Health using your member ID.
Key facts
Network Health serves Wisconsin with both commercial and Medicare Advantage books — two distinct coverage rules apply: employer opt-in for commercial weight loss, and the statutory Part D exclusion for Medicare Advantage members.
Network Health plan materials
Wegovy's list price is $1,349/month; Novo Nordisk announced a reduction to approximately $675/month effective January 1, 2027.
Novo Nordisk press release, 2026
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare Advantage beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Network Health covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all Network Health Medicare Advantage and Part D plans. Network Health Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare Advantage beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries. Network Health's notable Medicare Advantage membership means many members searching this query are Medicare beneficiaries for whom the Bridge is the operative 2026 weight-loss pathway.
Commercial / Employer
Group & marketplace plans
Network Health commercial and employer plans cover Wegovy for weight loss only when the employer has purchased the anti-obesity benefit. Where the benefit is included, prior authorization is required: BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), plus documented lifestyle program participation and weight-loss maintenance for renewal. If the employer did not opt in, weight-loss Wegovy is excluded — this is a benefit design decision, not a medical-necessity denial. ACA/individual-market plans generally exclude Wegovy for weight loss. Wisconsin Medicaid GLP-1 obesity coverage is state-dependent; verify on the WI Medicaid PDL. Per-plan drug tier and cost-share are not publicly published; verify via Network Health's drug-lookup tool. Commercially insured members whose plan covers Wegovy may use the NovoCare savings card at $25/month (max $100 per 28-day supply; not available to Medicare or Medicaid).
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where covered — not publicly published at the drug level. Confirm your specific cost-share on Network Health's drug-lookup tool or member portal. NovoCare savings card: commercially insured Network Health members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare Advantage beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan tier, deductible phase, and pharmacy — confirm with your Network Health plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your line of business: commercial or Medicare Advantage
Network Health has distinct commercial and Medicare Advantage books, and the coverage logic differs significantly. Commercial members need to check employer benefit design first. Medicare Advantage members face the statutory Part D weight-loss exclusion and should ask their prescriber about the CV indication or Medicare GLP-1 Bridge (launching July 1, 2026).
- 2
Search Network Health's drug-lookup tool for your specific plan
Go to networkhealth.com and use the formulary or drug-lookup tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm tier, PA requirements, and quantity limits for your actual plan.
- 3
Work with your prescriber on the right pathway
Commercial members: if your plan covers Wegovy, your doctor submits a PA with BMI documentation, comorbidities, and lifestyle program evidence. Medicare Advantage members: ask your prescriber whether you qualify for the CV indication or, from July 1, 2026, the Medicare GLP-1 Bridge at $50/month.
Options if Network Health won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide for T2D)
If you have type 2 diabetes, Ozempic (semaglutide) is broadly covered for T2D with PA across most commercial and Medicare plans regardless of the anti-obesity benefit. Ozempic is not FDA-approved for weight loss and should not be prescribed for that indication.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
Network Health covers Wegovy for weight loss on commercial plans only where the employer purchased the anti-obesity benefit. Drug-level Wegovy detail is not publicly published, so verify on the drug-lookup tool at networkhealth.com or by calling member services. ACA/individual plans generally exclude weight-loss GLP-1s. For Medicare Advantage members, the statutory Part D exclusion applies to weight loss — only the cardiovascular indication and, from July 1, 2026, the Medicare GLP-1 Bridge provide insured access.
Both Network Health and Quartz are Wisconsin regional plans with not-publicly-published Wegovy formulary detail, and both gate weight-loss coverage on employer opt-in for commercial members. The key distinction is that Network Health has a notable Medicare Advantage book, making the Part D statutory exclusion and the Medicare GLP-1 Bridge directly relevant to a larger share of its members. Quartz is a provider-owned cooperative with a primarily commercial and individual book. The verification advice is the same — check your plan's drug-lookup tool and HR — but Medicare Advantage members at Network Health should specifically ask about the CV indication and Bridge.
No. Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all Network Health Medicare Advantage plans. Network Health Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication with PA for members with established CVD. Starting July 1, 2026, the Medicare GLP-1 Bridge provides weight-loss access at $50/month outside Part D for eligible beneficiaries — eligibility requires BMI 35 or higher, or BMI 30 with heart failure, uncontrolled hypertension, or CKD, or BMI 27 with prediabetes, prior MI, prior stroke, or PAD.
Where the anti-obesity benefit is included in the commercial plan, Network Health requires PA with BMI 30 or higher (or 27 with a weight-related comorbidity), documented lifestyle program participation, and demonstrated weight-loss progress for renewal. Specific criteria are not publicly published — confirm with Network Health member services or your prescriber. For the Medicare CV indication, PA requires documented established CVD plus overweight or obese status.
Commercially insured Network Health members whose plan covers Wegovy may use the NovoCare savings card to pay as little as $25/month (up to $100 savings per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries. Network Health Medicare Advantage members cannot use the savings card due to federal anti-kickback rules.
Related Articles
Does BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Regence Cover Wegovy? 2026 Coverage Guide | Curex
Regence covers Wegovy for weight loss only where your employer opted in — the formulary is not publicly published. Medicare covers the CV indication only.
Read moreDoes Wellcare Cover Wegovy? Medicare Bridge 2026 | Curex
Wellcare Part D cannot cover Wegovy weight loss by law. Covers CV risk reduction with PA. Eligible members access $50/mo GLP-1 Bridge from July 2026.
Read moreWhether or not Network Health covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Network Health before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.